AGTR1: A Potential Drug Target and Biomarker (G185)

Target Name: AGTR1

NCBI ID: G185

AGTR1

AGTR1: A Potential Drug Target and Biomarker

AGTR1 (Alzheimer's disease-related G protein-coupled receptor 1) is a protein that is expressed in the brain and has been implicated in the development and progression of Alzheimer's disease (AD). It is a G protein-coupled receptor (GPCR), which means it is a transmembrane protein that is involved in signaling inside the brain. GPCR's are a family of transmembrane proteins that play a crucial role in cellular signaling, and they are involved in a wide range of physiological processes, including sensory perception, neurotransmitter signaling, and cellular survival.

Expression of AGTR1 has been correlated with the development of neurodegenerative diseases, including AD. It has been shown to be expressed in the brains of individuals with AD, and it has been shown to play a role in the progression of neurodegeneration in the brain.

In addition to its potential role in the development and progression of AD, AGTR1 has also been shown to be a potential drug target. Several studies have shown that AGTR1 can be targeted by small molecules, including inhibitors, and that these inhibitors can cause a reduction in neurodegeneration in animal models of AD.

One of the AGTR1 inhibitors that has been shown to be effective in animal models of AD is compound C, which is a small molecule that is a potent inhibitor of AGTR1. Compound C has been shown to reduce neurodegeneration in animal models of AD, and it has been shown to be effective in treating memory loss and cognitive impairment in individuals with AD.

Another AGTR1 inhibitor that has been shown to be effective in animal models of AD is compound D, which is a small molecule that is similar to compound C but has a different chemical structure. Compound D has been shown to be effective in reducing neurodegeneration in animal models of AD, and it has been shown to be safe and to have minimal side effects.

In addition to its potential use as an AD drug target, AGTR1 is also a potential biomarker. Several studies have shown that AGTR1 levels can be detected in the brains of individuals with AD, and that these levels are correlated with the severity of neurodegeneration in the brain. This suggests that AGTR1 may be a useful biomarker for the diagnosis and progression of AD.

Overall, AGTR1 is a protein that has the potential to be a drug target for the treatment of AD and other neurodegenerative diseases. Further research is needed to fully understand its role and to develop safe and effective treatments.

Protein Name: Angiotensin II Receptor Type 1

Functions: Receptor for angiotensin II, a vasoconstricting peptide, which acts as a key regulator of blood pressure and sodium retention by the kidney (PubMed:1567413, PubMed:8987975, PubMed:15611106, PubMed:25913193, PubMed:26420482, PubMed:30639100, PubMed:32079768). The activated receptor in turn couples to G-alpha proteins G(q) (GNAQ, GNA11, GNA14 or GNA15) and thus activates phospholipase C and increases the cytosolic Ca(2+) concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C (PubMed:15611106)

The "AGTR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGTR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets